Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of *Helicobacter pylori* infection

Michael Selgrad, Ina Tammer, Cosima Langner, Jan Bornschein, Julia Meißle, Arne Kandulski, Mariya Varbanova, Thomas Wex, Dirk Schlüter, Peter Malfertheiner

**Abstract**

**AIM:** To assess whether antibiotic resistance varies between the antrum and corpus of the stomach of patients that are either *Helicobacter pylori* (*H. pylori*) therapy-naïve or pre-treated.

**METHODS:** *H. pylori* strains were isolated from antrum and corpus biopsies from 66 patients that received a diagnostic gastroduodenoscopy for variant clinical indications. Antimicrobial susceptibility to amoxicillin, clarithromycin, tetracycline, metronidazole, levofloxacin and rifabutin was tested with the E-test method on Iso-Sensitest agar with 10 vol% defibrinated horse blood. In patients with a different antibiotic susceptibility pattern between the isolates from the antrum and corpus, DNA fingerprinting via random amplified polymorphic DNA analysis was performed to detect differences among DNA patterns of *H. pylori* isolates.

**RESULTS:** Primary, secondary and tertiary resistance to clarithromycin was 6.9%, 53.8% and 83.3%, respectively. Metronidazole and levofloxacin resistance also increased according to the number of previous treatments (17.2%, 69.2%, 83.3%; 13.8%, 23.1%, 33.3%). Tertiary resistance to rifabutin was detected in 12.5% of patients. In none of the 66 patients a resistance against amoxicillin or tetracycline was detectable. Discordant antibiotic susceptibility between antrum and corpus isolates for different antibiotics was seen in 15.2% (10/66) of the patients. Two out of those ten patients were naive to any *H. pylori* antibiotic treatment. The remaining eight patients previously received at least one eradication therapy. DNA fingerprinting analysis revealed no substantial differences among DNA patterns between antrum and corpus isolates in the majority of patients suggesting an infection with a single *H. pylori* strain.

**CONCLUSION:** Different antibiotic susceptibility between antrum and corpus biopsies is a common phenomenon and a possible explanation for treatment failure. Resistant *H. pylori* strains may be missed if just one biopsy from one anatomic site of the stomach is taken for *H. pylori* susceptibility testing.
failure. Resistant Helicobacter pylori (H. pylori) strains, as a possible reason for treatment failure may be missed in a reasonable number if just one biopsy from one anatomic site of the stomach is taken for H. pylori susceptibility testing.

Selgrad M, Tammer I, Langner C, Bornschein J, Meißle J, Kandulska A, Varbanova M, Wex T, Schlüter D, Mallertheiner P. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014; 20(43): 16245-16251 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i43/16245.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i43.16245

INTRODUCTION

Helicobacter pylori (H. pylori) is a gram-negative bacterium that chronically infects the human gastric mucosa. Infection with H. pylori is the main cause of chronic gastritis, peptic ulcer disease, low grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma[8,9]. The recognition of H. pylori as the key pathogen in various gastroduodenal diseases with various clinical manifestations has posed an increasing demand for therapeutic strategies. The development of effective treatment options for H. pylori infection was leading to an enormous change in the clinical management of gastroduodenal diseases with curative antibiotic therapeutic strategies for H. pylori related diseases such as low-grade gastric MALT lymphoma and H. pylori related peptic ulcer disease[10]. The worldwide and frequent use of antibiotic therapies in general and for H. pylori infection in particular is the reason for an increasing number of H. pylori eradication failures over the last decade[5]. The explanation for this phenomenon is the increasing antimicrobial resistance seen in many countries, in particular against clarithromycin[11]. Several national and international guidelines provide clear recommendations for first and second line treatment options for the treatment of H. pylori infection[11-13]. According to the European Maastricht consensus, following second line treatment failure, rescue treatment should be guided according to antimicrobial susceptibility testing, if available. However, there are no recommendations whether one or more gastric biopsies need to be taken for the assessment of H. pylori resistance to antibiotics. Because of the patchy distribution of H. pylori in the gastric mucosa, biopsies from several sites of the stomach might increase the diagnostic yield for the detection of H. pylori[14]. Additionally, H. pylori strains from one individual patient have usually either an antibiotic resistant or susceptible phenotype. However, both antibiotic susceptible and -resistant H. pylori strains may be present in the same patient[15]. H. pylori infection with differing antimicrobial susceptibilities in different parts of the stomach is likely to negatively affect the success of eradication therapies. This led to the hypothesis whether biopsies from the antrum and corpus can increase the diagnostic yield in order to optimise H. pylori antibiotic susceptibility guided therapy.

Therefore, we examined H. pylori antibiotic resistance in patients from biopsies simultaneously taken from the antrum and corpus to detect possible different antibiotic resistance pattern in individual patients.

MATERIALS AND METHODS

This study presents a retrospective analysis to evaluate the prevalence of H. pylori antibiotic resistance by analysing H. pylori isolates from antrum and corpus.

Data collection and patient characteristics

The electronic patient documentation system of the Department of Gastroenterology, Hepatology and Infectious Diseases at the University Hospital of Magdeburg, Germany, was used to retrieve all patients that underwent upper gastrointestinal endoscopy for H. pylori antibiotic susceptibility testing in the period between January 2010 and October 2012. Furthermore, patients were just considered for inclusion in the study that received biopsies for antibiotic susceptibility testing from the antrum and corpus of the stomach. In total, 66 patients, 50 females and 16 males met these criteria. The mean age of the patients was 52.54 ± 14.50 years. Out of these patients, 43 had a chronic gastritis, 18 had an atrophic gastritis, 2 had gastric ulcer and 3 suffered from adenocarcinoma of the stomach. Most of the patients included in the study (n = 37; 56.1%) were previously treated for H. pylori infection. Twenty-nine patients (43.9%) were naive to any H. pylori eradication therapy. Thirteen (19.7%) and 24 patients (36.4%) underwent one and 2 or more eradication therapies, respectively, before antibiotic susceptibility testing.

Ethics

The study was designed with respect to the corresponding sections of the “World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects”. Due to the retrospective character of our study that analyzed already realized medical treatments, approval of an IRB was not obtained. Written informed consent prior to endoscopic treatment and prior to data analyzing was given by all patients.

Diagnosis of H. pylori and histopathological assessment

Histopathological alterations of the gastric mucosa were assessed according to the updated Sydney system. Biopsies were processed by routine methods. One section was stained with hematoxilin and eosin, modified Giemsa for diagnosis of H. pylori, and PAS stain. H. pylori infection status was further assessed by rapid urease test (Campylobacter-like organism-test, Kimberly-Clark, Rosewell, United States).

Gastric biopsy specimen (one biopsy each from the antrum and corpus) were carried in Portagerm pylori tubes (bioMerieux, France) and culture was performed
on Columbia-agar-based medium that contained 10 vol% washed human erythrocytes and 10 vol% heat inactivated horse serum (purchased from the NRZ Nationale Referenzzentrum Helicobacter Freiburg, Germany) without and with antibiotic supplement (vancomycin 10 mg/mL; nystatin 1 mg/mL and trimethoprim 5 mg/mL) to suppress the overgrowth of the oral flora \(^{[11,12]}\). Incubation of the plates was performed under microaerophilic conditions at 37\(^\circ\) Celsius by using CampyGen™ gasbags (Oxoid, Germany) and examination was done every 2-3 d for up to 10 d. Identification of \(H.\ pylori\) was performed by typical morphology on Gram stain and positive urease, oxidase, and catalase tests.

Susceptibility testing to amoxicillin, clarithromycin, tetracycline, metronidazole, levofloxacin and rifabutin was performed with the Etest method (bioMerieux, France) on Iso-Sensitst agar with 10 vol% defibrinated horse blood (Oxoid, Germany)\(^{[13,14]}\). This test is useful for analysing slow-growing bacteria with fastidious growth requirements. It is minimally affected by the size of the inoculum or the duration of incubation, and therefore this method is reliable and simple enough to be used routinely. The Etest is able to detect antibiotic-resistant subpopulations. In this study, agar plates were treated with suspensions of \(H.\ pylori\) after adjustment to a turbidity approximately equal to that of a McFarland standard No. 3. Determination of the Minimum inhibitory concentrations (MICs) of the antibiotics was carried out after 3 d of incubation or until the inhibition zone became visible. A resistant isolate was defined if the MIC was above the following breakpoints: amoxicillin, clarithromycin, tetracycline and levofloxacin > 1 mg/L; rifabutin > 4 mg/L and metronidazole > 8 mg/L\(^{[15]}\).

**DNA fingerprinting via random amplified polymorphic DNA analysis**

In patients with a different antibiotic susceptibility pattern between the isolates from the antrum and corpus, \(H.\ pylori\) DNA was extracted from single colony isolates using QIAamp DNA mini Kit (Qiagen, Hilden, Germany). The specific \(H.\ pylori\) decanucleotide primers 1254, 1281, and 1290 were applied for DNA fingerprinting via random amplified polymorphic DNA analysis (RAPD-PCR). RAPD-PCR was carried out in a 27 \(\mu\)L volume, using 20 ng of \(H.\ pylori\) genomic DNA, 20 pmol of each primer, 1.5 U of AmpliTaq DNA polymerase, 250 mmol/L of deoxynucleotide triphosphate, and 3 mmol/L MgCl\(_2\) in standard PCR-buffer. Amplifications consisted of 40 cycles of 94 \(^\circ\)C (1 min), 36 \(^\circ\)C (1 min), 72 \(^\circ\)C (2 min), and 72 \(^\circ\)C (10 min). All RAPD-PCR amplifications were performed three times to confirm reproducibility of the results. Analysis of the PCR fragments was performed by electrophoresis in a 2% agarose gel under 95 voltages for 3 h. The following criteria were used for the classification of the fingerprint patterns: (1) identical when fingerprint patterns had exactly the same pattern; (2) similar or degenerate when fingerprints had the same patterns with additional or different size of bands; or (3) different when the fingerprints had totally different patterns.

**Statistical analysis**

The Fisher’s exact test with a 95% confidence interval was used to define differences in the proportion of patients with susceptible and resistant \(H.\ pylori\) strains. \(P\) values were considered significant when \(P < 0.05\).

**RESULTS**

**Overall antibiotic susceptibility**

All 132 successfully cultured \(H.\ pylori\) isolates from the two gastric sites (antrum and corpus) of the 66 patients were assayed against amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracyclin, and rifabutin (Table 1). Antibiotic resistance to clarithromycin was seen in 29 patients (43.9%) and in 34 patients (51.5%) a resistance to metronidazole was detected. Antibiotic resistance to both clarithromycin and metronidazole was found in 18 of the 29 strains. Levofloxacin resistance was found in 15 (22.7%) patients, while rifabutin resistance was seen in 3 (4.5%) patients. In none of the patients a resistance against amoxicillin or tetracycline was detectable.

In the 29 patients (43.9%) that have not received any eradication therapy before \(H.\ pylori\) susceptibility testing, primary resistance against clarithromycin was 6.9% (\(n = 2\)). Primary resistance against metronidazole and levofloxacin was a bit higher with 17.2% (\(n = 5\)) and 13.8% (\(n = 4\)) in those patients. Thirteen patients underwent one eradication attempt before resistance testing. In those patients resistance against clarithromycin and metronidazole was high with 53.8% (\(n = 7\)) and 69.2% (\(n = 9\)). Levofloxacin resistance was detectable in three out of those 13 patients (23.1%).

Twenty-four patients (36.4%) received at least more than two eradication therapies. In those patients, clarithromycin resistance was expectably high with 83.3% (\(n = 20\)). A comparably high rate with 83.3% (\(n = 20\)) and 33.3% (\(n = 8\)) was also seen for metronidazole and levofloxacin. Rifabutin resistance was detected in three patients (12.5%) that all received multiple eradication therapies. The overall antibiotic resistance increased significantly in accordance to the number of eradication therapies (\(P < 0.001\)). Table 2 gives an overview about the resistance data regarding the number of previous eradication attempts.

| Antibiotic       | Patients with resistant \(H.\ pylori\) strains | 95%CI  |
|------------------|---------------------------------------------|--------|
| Amoxicillin      | 0 (0)                                       | 0.00-0.00 |
| Clarithromycin   | 29 (43.9)                                   | 0.32-0.56 |
| Metronidazole    | 34 (51.5)                                   | 0.39-0.64 |
| Tetracycline     | 0 (0)                                       | 0.00-0.00 |
| Levofloxacin     | 15 (22.7)                                   | 0.09-0.28 |
| Rifabutin        | 3 (4.5)                                     | 0.01-0.04 |
Antibiotic heteroresistance, a reason for *H. pylori* treatment failure

**Table 2** Antibiotic resistance of *Helicobacter pylori* strains depending on the number of eradication therapies n (%)

| Patients with resistant *Helicobacter pylori* strains | 95% CI |
|------------------------------------------------------|--------|
| No previous eradication therapy (n = 29)             |        |
| Clarithromycin                                      | 0.03-0.18 |
| Metronidazole                                       | 0.03-0.34 |
| Levofloxacin                                        | 0.02-0.24 |
| One previous eradication therapy (n = 13)            |        |
| Clarithromycin                                      | 0.30-0.98 |
| Metronidazole                                       | 0.30-0.98 |
| Levofloxacin                                        | 0.04-0.59 |
| Two or more previous eradication therapies (n = 24)  |        |
| Clarithromycin                                      | 0.63-0.97 |
| Metronidazole                                       | 0.69-0.99 |
| Levofloxacin                                        | 0.09-0.47 |
| Rifabutin                                            | 0.04-0.12 |

**Table 3** Antibiotic susceptibility in patients with discordant resistance pattern between antrum and corpus biopsies

| Patients | Clarithromycin | Metronidazole | Levofloxacin | Rifabutin |
|----------|----------------|---------------|--------------|-----------|
| Patient 1| Antrum         | Resistant     | Susceptible  | Susceptible |
| Corpus   | Susceptible    | Resistant     | Susceptible  | Susceptible |
| Patient 2| Antrum         | Susceptible   | Susceptible  | Susceptible |
| Corpus   | Susceptible    | Susceptible   | Susceptible  | Susceptible |
| Patient 3| Antrum         | Resistant     | Resistant    | Susceptible |
| Corpus   | Susceptible    | Susceptible   | Susceptible  | Susceptible |
| Patient 4| Antrum         | Resistant     | Susceptible  | Susceptible |
| Corpus   | Resistant      | Susceptible   | Susceptible  | Susceptible |
| Patient 5| Antrum         | Susceptible   | Susceptible  | Susceptible |
| Corpus   | Susceptible    | Susceptible   | Susceptible  | Susceptible |
| Patient 6| Antrum         | Resistant     | Susceptible  | Susceptible |
| Corpus   | Resistant      | Susceptible   | Susceptible  | Susceptible |
| Patient 7| Antrum         | Susceptible   | Susceptible  | Susceptible |
| Corpus   | Susceptible    | Susceptible   | Susceptible  | Susceptible |
| Patient 8| Antrum         | Resistant     | Susceptible  | Susceptible |
| Corpus   | Resistant      | Susceptible   | Susceptible  | Susceptible |
| Patient 9| Antrum         | Resistant     | Susceptible  | Susceptible |
| Corpus   | Resistant      | Susceptible   | Susceptible  | Susceptible |
| Patient 10| Antrum       | Resistant     | Susceptible  | Susceptible |
| Corpus   | Resistant      | Susceptible   | Susceptible  | Susceptible |

**Antibiotic susceptibility at different gastric sites (antrum and corpus)**

The overall prevalence of patients infected simultaneously with susceptible and resistant *H. pylori* strains was 15.2% (10/66). Two out of those ten patients were naive to any *H. pylori* antibiotic treatment. The remaining eight patients previously received at least one eradication therapy. Six patients had in the past at least two eradication therapies, while the remaining two patients had one eradication attempt.

A different antibiotic susceptibility pattern between antrum and corpus biopsies against two different antibiotics was detected in three patients, while seven patients showed a discordant susceptibility against one antibiotic agent. In two patients resistance against clarithromycin was detectable in the antrum, while the corpus biopsy was susceptible against clarithromycin. A comparable result was found for metronidazole. Four patients showed a resistance in the antrum, while metronidazole sensitivity was seen in the corpus. In five patients a discordant antibiotic resistance against levofloxacin was detectable. Two levofloxacin-resistant strains were detected in the antrum and three resistant strains in the corpus, while the biopsies from the different stomach site were susceptible for levofloxacin. Different antibiotic resistance against rifabutin was determined in two patients (2.8%) that showed susceptibility in the antrum and resistance in the corpus. All ten patients simultaneously infected with susceptible and resistant *H. pylori* strains were successfully treated and sensitivity to the same antibiotic in the same host was available for nine out of the ten patients. In eight patients who where all previously treated for *H. pylori* infection besides one patient no substantial differences from the DNA pattern of the antrum and corpus isolates were detectable suggesting an infection with a single *H. pylori* strain in the stomach. In only one patient a difference in the DNA pattern between antrum and corpus was proven suggesting a mixed infection in this patient. This patient received one eradication attempt previously (Figure 1). From a clinical point of view, eight patients suffered from chronic gastritis, while one patient was diagnosed with gastric cancer.

**Epidemiological data**

No statistical significance was observed for differences in age, gender and gastric diseases of the patients included in the study. Furthermore, the analysis of the distribution and histological grade of activity of the gastritis (antrum vs corpus) did not reveal any difference for the patients with discordant antibiotic susceptibility between antrum and corpus isolates (data not shown).

**DISCUSSION**

In our study, we demonstrate that different antibiotic susceptibility between antrum and corpus biopsies is a common phenomenon and occurs in eradication naive as well in previously treated patients.

**DNA fingerprinting**

Due to the retrospective character of our study, DNA isolation of *H. pylori* isolates from patients with resistance and sensitivity to the same antibiotic in the same host was
In agreement with previous studies, we found a comparably high discordant antibiotic susceptibility to clarithromycin and metronidazole between antrum and corpus biopsies\[10,15,16\]. Interestingly, clarithromycin resistance in the heteroresistance cases was exclusively detected in antrum biopsies, which is in disagreement with previous studies that showed a higher rate of resistant isolates in the corpus\[15,17\]. In particular, the resistance against clarithromycin affects the treatment success of standard triple therapy and the knowledge of clarithromycin resistance is crucial for the recommendation of first-line therapy\[18\]. In regions with a clarithromycin resistance higher than 20%, clarithromycin based triple therapy should not be used. In this case, quadruple therapy should be applied\[19\]. Our data clearly confirm previous studies that demanded multiple gastric biopsies from different sites of the stomach to detect clarithromycin resistant strains\[15,16\]. According to our results there is a reasonable chance to underestimate or miss clarithromycin resistance if just one biopsy is taken for antimicrobial susceptibility testing. This might certainly negatively affect the treatment success of H. pylori therapy. This is of particular clinical interest both for patients receiving first-line and patients receiving antibiotic susceptibility guided rescue therapy. In our study, we took biopsies and tested them for antibiotic susceptibility separately from the antrum and corpus of the stomach. From a practical point of view and considering economical aspects, the biopsies from the antrum and corpus can be cultured together.

Another interesting aspect of our study is the detection of discordant antibiotic susceptibility to levofloxacin and rifabutin. To our knowledge, this is one the first reports that describes this discordance between antrum and corpus biopsies for these two antibiotic agents. After failure of first-line options, levofloxacin based triple therapy is currently recommended as a possible second-line therapy. Thus, it is a widely used antibiotic agent for H. pylori infection and recent data show increasing resistance rates to levofloxacin\[4\]. Rifabutin is widely accepted as an important part of H. pylori rescue therapy\[20\]. The detected discordant antibiotic susceptibility to the two antibiotics is in our opinion of great clinical importance for patients receiving second-line or rescue therapies.

One of the most intriguing aspects of the study is the result of the DNA-fingerprinting analysis of the H. pylori isolates of the patients with a discordant antibiotic susceptibility result between antrum and corpus isolates. Eight of the nine patients showed identical fingerprinting patterns suggesting an infection with a single H. pylori strain. Only in one patient substantial difference in the DNA pattern was detectable suggesting a mixed infection. This finding is in agreement with a previous study showing that DNA fingerprinting patterns of each pairs of isolates from the antrum and corpus are identical or at least similar suggesting that antibiotic resistant H. pylori strains typically develop from a pre-existing susceptible strain rather than co-infection with a different strain\[10\]. This finding might be also an explanation for our results, because the majority of patients (seven out of eight) with a single infection, but discordant antibiotic susceptibility were pre-treated and under these stress conditions (previous antibiotic treatment) alterations in the genomic DNA occur, which may affect the phenotype of H. pylori. However our results are in disagreement with another study demonstrating substantial differences among DNA patterns between isolates of the proximal and distal stomach suggesting a mixed infection\[21\]. However, in this study the majority of patients were never treated before testing which might give an explanation for the disagreement.

A weakness of our study represents the fact that the
information about the exact composition of previous *H. pylori* eradication therapies that a single patient received is unavailable. It is well known, that the resistance rates are increasing significantly in dependency of the number of previously prescribed eradication therapies\(^{22,23}\). The primary resistance rates in our study was comparable to other studies conducted in Europe\(^{22,23}\), but it has to be noted that the primary resistance rate against clarithromycin was more than three times higher than in a study that was conducted in our department from the year 1995 till 2000\(^{24}\). The knowledge about previous *H. pylori* eradication therapies could at least partially explain the high resistance rates against clarithromycin, metronidazole and levofloxacin in our patient population. One can just speculate that the majority of patients included in our study received as first-line therapy clarithromycin based standard triple and as second line levofloxacin based triple therapy, as recommended in the German S3-guidelines\(^7\).

It is well known, that especially in case of clarithromycin, the resistance rate is dramatically increasing after its first use and thus this might give the explanation for the high clarithromycin resistance in our study population. Another important point is that we could not gather an accurate history on the intake of other medications due to the retrospective character of our study. We carefully analysed our electronic patient data system, however it is possible that we missed important information about previous antibiotic intake for other clinical indications. Clarithromycin and levofloxacin are important antibiotic agents often used for other infectious diseases, such as respiratory tract infections\(^{25}\), and this may be an explanation for the high resistance rates seen in our study.

In conclusion, different antibiotic susceptibility between antrum and corpus biopsies can occur in naïve and pre-treated patients and in our population it is caused by an infection with a single *H. pylori* strain. This finding indicates that *H. pylori* antibiotic resistant strains may be missed if biopsies for culture are taken only from one location and offers a possible explanation for treatment failure. Thus antibiotic susceptibility guided therapy by taking just one biopsy from one single site of the stomach might not be considered representative. Therefore, we suggest taking one separate biopsy from the antrum and corpus in patients undergoing endoscopy for *H. pylori* antibiotic susceptibility guided therapy.

**ACKNOWLEDGMENTS**

The authors wish to thank Professor Luigiina Cellini and Leonardo Marzio (University “G. d’Annunzio”, Chieti-Pescara, Italy) for providing their expertise and primer sequences for the RAPD-PCR.

**REFERENCES**

1. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302884]

2. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374: 1449-1461 [PMID: 19683340 DOI: 10.1016/S0140-6736(09)60938-7]

3. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011; 27: 565-570 [PMID: 21964269 DOI: 10.1097/MOG.0b013e32835b818]

4. Megraud F, Coenens S, Versporten A, Kist M, Lopez-Brea M, Hirsch AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]

5. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Munakami K, Satoh K, Sugano K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x]

6. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HH, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiha T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]

7. Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Götze O, Höhne W, Kist M, Koletzko S, Labenz J, Layer P, Miehlke S, Morgan R, Peitz U, Preiss J, Prinz C, Rosien U, Schmidt W, Schwarzer A, Suerbaum S, Timmer J, Layer P, Miehlke S, Morgner A, Peitz U, Preiss J, Prinz C, Rosien U, Schmidt W, Schwarzer A, Suerbaum S, Timmer J, Layer P, Miehlke S. Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for hygiene and microbiology, society
Selgrad M et al. Antibiotic heteroresistance, a reason for H. pylori treatment failure

for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47: 1230-1263 [PMID: 19960402 DOI: 10.1055/s-0028-1109855]

8 Goodwin CS, Worsley BW. Microbiology of Helicobacter pylori. Gastroenterol Clin North Am 1993; 22: 5-19 [PMID: 8449570]

9 Bayerdorffer E, Oertel H, Lohn N, Kasper G, Mannes GA, Sauerbruch T, Stolte M. Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol 1989; 42: 834-839 [PMID: 2768523 DOI: 10.1136/jcp.42.8.834]

10 Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 202-206 [PMID: 12752732 DOI: 10.1046/j.1523-5378.2003.00145.x]

11 Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322 [PMID: 17429887 DOI: 10.1128/CMR.00033-06]

12 Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother 2009; 63: 648-653 [PMID: 19190100 DOI: 10.1093/jac/dkp003]

13 Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 1993; 31: 65-71 [PMID: 8444676 DOI: 10.1093/jac/31.1.65]

14 Głuczynski Y, Labbé M, Hansen W, Crokaert F, Youargasowski E. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol 1991; 29: 2072-2075 [PMID: 1774337]

15 Ayala G, Galván-Portillo M, Chihu L, Fierros G, Sánchez A, Carrillo B, Román A, López-Carrillo L, Silva-Sánchez J. Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico. Microb Drug Resist 2011; 17: 149-155 [PMID: 21303219 DOI: 10.1089/mdr.2010.0154]

16 Rimbara E, Noguchi N, Tanabe M, Kawai T, Matsumoto Y, Sasatsu M. Susceptibilities to clarithromycin, amoxicillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. Clin Microbiol Infect 2005; 11: 507-511 [PMID: 15760428 DOI: 10.1111/j.1469-0691.2005.01099.x]

17 Youssi MM, Reddy R, Osato MS, Graham DY. Is antrum or corpus the best site for culture of Helicobacter pylori? Helicobacter 1996; 1: 88-91 [PMID: 9398884 DOI: 10.1111/j.1523-5378.1996.tb00116.x]

18 Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori pylori in the East and West. Expert Rev Anti Infect Ther 2011; 9: 581-588 [PMID: 21819326 DOI: 10.1586/eri.11.80]

19 Malfertheiner P, Bazzoli F, Delchier JC, Celiński K, Giugiùre M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancer 2011; 377: 905-913 [PMID: 21345487 DOI: 10.1016/S0140-6736(11)60020-2]

20 Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, Modolélli I, Cabriada JL, Gisbert JL, Lamas E, Marcos E, Calvet X. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35: 941-947 [PMID: 22372560]

21 Marzio L, Cellini L, Amitrano M, Grande R, Serio M, Capello G, Grossi L. Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. Eur J Gastroenterol Hepatol 2011; 23: 467-472 [PMID: 21537122 DOI: 10.1097/MEG.0b013e28834fd40f]

22 Karczewska E, Wojtas-Bonior I, Sito E, Zwolińska-Wcisło M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep 2011; 63: 799-807 [PMID: 21857091 DOI: 10.1016/S1734-1140(11)70592-8]

23 Raymond J, Lamarque D, Kalach N, Chaussade S, Baruca C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010; 15: 21-27 [PMID: 20302866]

24 Wolle K, Leodolter A, Malfertheiner P, König W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-709 [PMID: 12171304]

25 Torres A, Liapikou A. Levofloxacin for the treatment of respiratory tract infections. Expert Opin Pharmacother 2012; 13: 1203-1212 [PMID: 22594848 DOI: 10.1517/14656566.2012.688952]
